Sort
40,608 grants matching “prostate cancer”
Plasma and saliva biomarkers of disease status in HPV related oropharynx cancer
$387,831Joseph A Califano · University Of California, San Diego · R01 · FY2019 · CA
Role of GATA2 signaling network in Lethal Prostate Cancer
$387,799Josep Maria Domingo-Domenech · Thomas Jefferson University · R01 · FY2019 · CA
Tumor Immunology & Host Response
$387,787Max S. Wicha · University Of Michigan At Ann Arbor · P30 · FY2016 · CA
ANTITUMOR MECHANISMS &THERAPEUTIC EFFECTS OF VITAMIN D
$387,767University Of Pittsburgh At Pittsburgh · R01 · FY2000 · CA
Role of Tumor Stem Cells Recurrent Prostate Cancer
$387,762Gary Smith · Univ Of North Carolina Chapel Hill · P01 · FY2014 · CA
Developing therapeutics against resistance to the androgen-deprivation therapy
$387,731Qin Yu · Icahn School Of Medicine At Mount Sinai · R01 · FY2017 · CA
Coordinate Regulation of Oncogenic Signaling Pathways in SPOP Mutant Prostate Cancer
$387,731Christopher E Barbieri · Weill Medical Coll Of Cornell Univ · R37 · FY2020 · CA
Chronic inhibition of androgen receptor signaling leads to neuroendocrine prostate cancer by trans differentiation of stem/progenitor cells
$387,731David Mulholland · Icahn School Of Medicine At Mount Sinai · R01 · FY2018 · CA
Chronic inhibition of androgen receptor signaling leads to neuroendocrine prostate cancer by trans differentiation of stem/progenitor cells
$387,731David Mulholland · Icahn School Of Medicine At Mount Sinai · R01 · FY2015 · CA
Coordinate Regulation of Oncogenic Signaling Pathways in SPOP Mutant Prostate Cancer
$387,731Christopher E Barbieri · Weill Medical Coll Of Cornell Univ · R37 · FY2018 · CA
Harnessing Csf-2 compartmentalized role on tissue resident phagocytes to uncouple anti-tumoral from pathological immunity induced by checkpoint inhibitors
$387,731Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2016 · CA
Developing therapeutics against resistance to the androgen-deprivation therapy
$387,731Qin Yu · Icahn School Of Medicine At Mount Sinai · R01 · FY2016 · CA
Coordinate Regulation of Oncogenic Signaling Pathways in SPOP Mutant Prostate Cancer
$387,731Christopher E Barbieri · Weill Medical Coll Of Cornell Univ · R37 · FY2021 · CA
Chronic inhibition of androgen receptor signaling leads to neuroendocrine prostate cancer by trans differentiation of stem/progenitor cells
$387,731David Mulholland · Icahn School Of Medicine At Mount Sinai · R01 · FY2017 · CA
Developing therapeutics against resistance to the androgen-deprivation therapy
$387,731Qin Yu · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · CA
Harnessing Csf-2 compartmentalized role on tissue resident phagocytes to uncouple anti-tumoral from pathological immunity induced by checkpoint inhibitors
$387,731Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2015 · CA
Chronic inhibition of androgen receptor signaling leads to neuroendocrine prostate cancer by trans differentiation of stem/progenitor cells
$387,731David Mulholland · Icahn School Of Medicine At Mount Sinai · R01 · FY2016 · CA
Harnessing Csf-2 compartmentalized role on tissue resident phagocytes to uncouple anti-tumoral from pathological immunity induced by checkpoint inhibitors
$387,731Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2017 · CA
Developing therapeutics against resistance to the androgen-deprivation therapy
$387,731Qin Yu · Icahn School Of Medicine At Mount Sinai · R01 · FY2018 · CA
Coordinate Regulation of Oncogenic Signaling Pathways in SPOP Mutant Prostate Cancer
$387,731Christopher E Barbieri · Weill Medical Coll Of Cornell Univ · R37 · FY2022 · CA
GENE EXPRESSION PROFILING OF UNKNOWN PRIMARY CANCERS
$387,728Stanford University · R33 · FY2001 · CA
Hyperpolarized 13c NMR Studies of Prostate Cancer (RMI)
$387,701John Kurhanewicz · University Of California, San Francisco · R21 · FY2008 · EB
Prostate Cancer Recovery Enhancement (PROCARE) for African American Men
$387,697Lisa C Campbell · East Carolina University · R01 · FY2009 · CA
Translational Molecular and Cellular Imaging Technologies for Prostate Tumor Pathology
$387,693Rohit Bhargava · University Of Illinois At Urbana-Champaign · R33 · FY2016 · CA
SERUM RESPONSE FACTOR AS A NOVEL THERAPEUTIC TARGET IN PROSTATE CANCER
$387,642Health Research, Inc. · · FY2010 · Department of Defense